MSDC 0160

Drug Profile

MSDC 0160

Alternative Names: Mitoglitazone; MSDC-0160

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator Metabolic Solutions Development Company
  • Developer Metabolic Solutions Development Company; PKD Foundation; Van Andel Research Institute
  • Class Antihyperglycaemics; Small molecules; Thiazolidinediones
  • Mechanism of Action Mitochondrial protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • Preclinical Parkinson's disease; Polycystic kidney disease
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 07 Dec 2016 Van Andel Research Institute and Metabolic Solutions Development Company announce intention to initiate clinical trials for Parkinson's disease in 2017
  • 11 Sep 2013 Discontinued - Phase-II for Type-2 diabetes mellitus in USA (PO)
  • 09 Jun 2012 Preclinical trials in Parkinson's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top